BioCardia Inc
BCDA1.250USD
+0.010+0.81%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
13.26MMarket Cap
LossP/E TTM
More Details of BioCardia Inc Company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
BioCardia Inc Info
Ticker SymbolBCDA
Company nameBioCardia Inc
IPO dateNov 13, 1996
CEOAltman (Peter)
Number of employees17
Security typeOrdinary Share
Fiscal year-endNov 13
Address320 Soquel Way
CitySUNNYVALE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94085
Phone16502260123
Websitehttps://www.biocardia.com/
Ticker SymbolBCDA
IPO dateNov 13, 1996
CEOAltman (Peter)
Company Executives of BioCardia Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
636.06K
+491522.00%
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
273.87K
+5000.00%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
79.40K
-39289.00%
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
76.89K
+28937.00%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
--
Mr. Bill Facteau
Mr. Bill Facteau
Independent Director
Independent Director
13.12K
--
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Independent Director
Independent Director
3.62K
--
Mr. Edward Gillis
Mr. Edward Gillis
Senior Vice President - Devices
Senior Vice President - Devices
--
--
Mr. Marvin L. Slosman
Mr. Marvin L. Slosman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
636.06K
+491522.00%
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
273.87K
+5000.00%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
79.40K
-39289.00%
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
76.89K
+28937.00%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
7.54%
Satterfield (Thomas A Jr)
6.93%
Blank (Andrew Scott)
5.99%
Altman (Peter)
2.58%
The Vanguard Group, Inc.
1.28%
Other
75.68%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
7.54%
Satterfield (Thomas A Jr)
6.93%
Blank (Andrew Scott)
5.99%
Altman (Peter)
2.58%
The Vanguard Group, Inc.
1.28%
Other
75.68%
Shareholder Types
Shareholders
Proportion
Individual Investor
18.63%
Corporation
8.10%
Investment Advisor
3.31%
Investment Advisor/Hedge Fund
0.70%
Hedge Fund
0.29%
Venture Capital
0.15%
Research Firm
0.01%
Other
68.81%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
38
427.14K
3.11%
--
2025Q3
39
427.14K
3.75%
+122.75K
2025Q2
40
304.39K
6.59%
+58.52K
2025Q1
42
245.87K
5.80%
-25.66K
2024Q4
44
124.90K
5.52%
+23.37K
2024Q3
42
101.53K
8.19%
+14.85K
2024Q2
45
86.68K
14.23%
-43.02K
2024Q1
45
129.71K
18.77%
-204.85K
2023Q4
44
137.17K
19.64%
-40.91K
2023Q3
42
178.26K
20.96%
-3.53K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
800.00K
7.54%
+800.00K
--
Sep 19, 2025
Satterfield (Thomas A Jr)
736.00K
6.93%
+400.00K
+119.05%
Sep 30, 2025
Blank (Andrew Scott)
636.06K
5.99%
+491.52K
+340.07%
Sep 30, 2025
Altman (Peter)
267.97K
2.52%
+51.20K
+23.62%
Dec 17, 2025
The Vanguard Group, Inc.
96.50K
0.91%
+83.61K
+648.98%
Sep 30, 2025
CM Management, LLC
130.00K
1.22%
--
--
Sep 30, 2025
Allen (Jim L)
109.66K
1.03%
--
--
Sep 30, 2025
Stertzer (Simon H)
79.40K
0.75%
-39.29K
-33.10%
Sep 30, 2025
Mcclung (David)
76.89K
0.72%
+28.94K
+60.35%
Dec 08, 2025
Stertzer Family Trust
59.20K
0.56%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
Date
Ex-dividend Date
Type
Ratio
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
May 21, 2024
Merger
15→1
